Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells
AbstractLambertianic acid (LA) is known to have anti-allergic and antibacterial effects. However, the anticancer activities and mechanism of action of LA have not been investigated. Therefore, the anticancer effects and mechanism of LA are investigated in this study. LA decreased not only AR protein levels, but also cellular and secretory levels of PSA. Furthermore, LA inhibited nuclear translocation of the AR induced by mibolerone. LA suppressed cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1 and activating p53 and its downstream molecules, p21 and p27. LA induced apoptosis and the expression of related proteins, including cleaved caspase-9 and -3, c-PARP and BAX, and inhibited BCl-2. The role of AR in LA-induced apoptosis was assessed by using siRNA. Collectively, these findings suggest that LA exerts the anticancer effect by inhibiting AR and is a valuable therapeutic agent in prostate cancer treatment. View Full-Text
- Supplementary File 1:
Supplementary (PDF, 606 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Lee, M.-S.; Lee, S.-O.; Kim, S.-H.; Lee, E.-O.; Lee, H.-J. Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells. Int. J. Mol. Sci. 2016, 17, 1066.
Lee M-S, Lee S-O, Kim S-H, Lee E-O, Lee H-J. Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells. International Journal of Molecular Sciences. 2016; 17(7):1066.Chicago/Turabian Style
Lee, Myoung-Sun; Lee, Seon-Ok; Kim, Sung-Hoon; Lee, Eun-Ok; Lee, Hyo-Jeong. 2016. "Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells." Int. J. Mol. Sci. 17, no. 7: 1066.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.